Pure Global
NCT06003426

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
Bristol-Myers Squibb·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Idiopathic Pulmonary Fibrosis
Drug/Device/Intervention
BMS-986278
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Bristol-Myers Squibb
Location
Birmingham,Jasper,Phoenix,La Jolla,La Jolla,Los Angeles,Los Angeles,Orange,Sacramento,San Francisco,Stanford,Aurora,Denver,New Haven,Newark,Washington,Brandon,Celebration,Clearwater,DeBary,Gainesville, Argentina,Australia,Austria,Belgium,Brazil,Canada,Chile,China,Colombia,Czech,Denmark,Finland,France,
Timeline & enrollment
Phase
Phase 3
Start date
Sep 14, 2023
End date
Oct 26, 2026
Enrollment
1185 participants
Primary outcome

Absolute change from baseline in forced vital capacity (FVC) measured in mL

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278
 in participants with Idiopathic Pulmonary Fibrosis.

ICD-10 classifications
Other interstitial pulmonary diseases with fibrosisCystic fibrosis with pulmonary manifestationsCystic fibrosisGraphite fibrosis (of lung)Pulmonary heart disease, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06003426
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06003426 through Pure Global AI's free database. This Phase 3 trial is sponsored by Bristol-Myers Squibb and is currently Recruiting. The study focuses on Idiopathic Pulmonary Fibrosis. Target enrollment is 1185 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.